Recent publications on Residual Risk

In the German DIVE (DIabetes Versorgungs-Evaluation) and the DPV (Diabetes-Patienten-Verlaufsdokumentation) database including more than 350,000 individuals, only a minority (26.7%) were treated with lipid modifying therapy, highlighting the need for further action to address this issue. <
 
This analysis included data from 363,949 individuals with type 2 diabetes. Of those who received lipid modifying treatment, the most commonly prescribed was statin (84%). While control of low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C) was significantly better (p<0.001) in these patients than in those not on a statin (median LDL-C 100.5 vs. 114.0 mg/dl in those not treated, and non-HDL-C 131.0 vs. 143.1 mg/dl, respectively), plasma triglycerides were significantly higher (160.3 vs. 152.0 mg/dl; p < 0.001). Thus, despite the availability of multiple guidelines, lipid management, particularly of triglycerides, lags behind in this high risk group.